Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the ...

Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing ...

By stimulating cancer cells to produce a molecule that activates a signaling pathway in nearby immune cells, MIT researchers have found a way to force tumors to trigger their own destruction.

In a breakthrough for diagnostics, scientists have created an easy and effective test that identifies a heart failure ...

Cardiologists need to know how to recognize and manage the cardiac effects that can arise from SARS-CoV-2 infections or COVID ...

The start of the trial marks an expansion of the firm's oncology pipeline, and the firm hopes mRNA-2808 will be the first of many T-cell engagers in its portfolio.